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Conclusion: these favorable results in large volume liver 
metastases from low grade NET, although derived from only 
two anedoctal cases, give support to the concept that the 
outcome of SBRT is relatively independent from tumor type, 
being mainly mediated by an ablative effect. Also they 
represent a typical example showing how repeat liver SBRT 
may lead to a a significant delay in disease progression 
although without achieving a definitive cure. 
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Purpose or Objective: To review stereotactic body radiation 
therapy (SBRT) safety and local control utility in malignant 
tumor of the pancreas based in a single center experience 
since February 2014. 
 
Material and Methods: A systematic review was done. 
Thirteen patients were treated with SBRT. Eleven patients 
had a primary pancreatic tumor and two patients had 
metastatic affectation of the pancreas. In those patients with 
primary pancreatic cancer, four patients were treated with a 
radical intent, five as a part of a neoadjuvant treatment and 
four patients with a palliative intent. All of the treated 
tumors had a diameter bigger than 2 cm. At least 2 fiducials 
were located into the tumor, guided by endoscopic 
ultrasound. All the treatments included CT or PET-CT for GTV 
delineation, intensity-modulated radiation therapy (IMRT) 
and image-guided radiation therapy (IGRT) with intrafraction 
control of tumor motion with a Novalis Exactrac Adaptive 
Gating System. 50 Gy in 10 fractions were prescribed in 
eleven patient, one patient was treated with 35Gy in 5 
fractions and one patient was treated with 40Gy in 10 
fraction. 
 
Results: Pancreatic SBRT was very well tolerated in our 
cohort of patients. No grade 3 or higher toxicity was 
observed. Only 3 patients developed grade 2 epigastric pain 
and/or grade 2 nausea/vomiting. The median patient age was 
62 years old (range 36 – 86 years) and the median follow-up 
was 14 months (range 2 – 18 months). Five patients under 
went surgery after SBRT. The median overall survival was 
14.5 months (range 2.4 – 18.2 months), with 65.3% survival at 
one year. Median survival time is 15 month (range 12 – 17 
months). Median time to local progression has not been 
reached. 
 
Conclusion: In our experience, gating SBRT for pancreatic 
tumor is a well-tolerated feasible treatment. Most patients 
are free from local progression, but overall survival remains 
poor. Prospective studies are needed to define the role of 
SBRT for pancreatic tumors. 
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Purpose or Objective: Stereotactic body radiotherapy (SBRT) 
in pancreatic cancer can be limited by its proximity to 
critical organs at risk (OAR) of the upper abdomen. In this 
study we evaluate the toxicity and efficacy of two different 
treatment approaches. 
 
Material and Methods: Patients with recurrent or 
oligometastatic pancreas cancer were treated with SBRT. The 
planning target volume (PTV) was created through a 4 mm 
expansion of the internal target volume (ITV) based on a four 
dimensional CT (4D-CT). All patients were treated with 
intensity modulated radiation therapy (IMRT). In some cases 
we created a sub-volume, in order to reduce the risk of 
toxicity in critical adjacent OARs without compensating the 
whole PTV. This sub-volume was defined as a simultaneous 
integrated protection (SIP) PTV. The SIP consisted of the 
interface of the PTV with the planning risk volume (PRV) of a 
specific vulnerable structure at which we prescribed a pre-
defined reduced dose. 
 
Results: Between 2009 and 2014, 18 patients with 23 lesions 
were treated in our institution. Seven patients were treated 
for a local recurrence, nine were treated for oligometastases 
(liver, lymph nodes) and two patients were treated for both. 
Of these lesions 11 were treated with SIP and 12 were 
treated without SIP. The median follow up was 10.8 months 
(range 1.2-40.3 months). The freedom from local progression 
(FFLP) at 6 and 12 months was 90% and 84% respectively. The 
overall survival (OS) rates at 6 months and 12 months after 
SBRT were 77% and 54%, respectively. Two patients (11%) 
experienced grade >3 acute toxicity (mechanical ileus, 
gastrointestinal bleeding) and 2 patients (11%) experienced a 
grade > 3 late toxicity (cholangitis, bleeding). 
 
Conclusion: Local control and overall survival after SBRT in 
this high risk group of patients with pancreatic cancer were 
excellent despite of dose sacrifice in half of the patients 
when OARs were close to the PTV, with overall favourable 
toxicity. 
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Purpose or Objective: To evaluate the efficacy and 
feasibility of stereotactic ablative radiotherapy (SABR) in the 
treatment of liver metastases. 
 
Material and Methods: We retrospectively analyzed patients 
with 1-2 secondary liver lesions treated with SABR. The total 
dose prescriptions were 30 Gy, 37.5 Gy and 45 Gy on three 
consecutive days in 42.8%, 22.8% and 34.4% of patients 
respectively. The dose was prescribed to the 80% isodose line 
covering the PTV. The primary endpoints were in field local 
control and toxicity; the secondary endpoint was survival 
rates. 
 
Results: Between March 2007 and May 2015, 30 patients (17 
males, 13 females) with 36 liver metastases were treated. 
The mean age was 66 years (range, 40-90 years). Twenty-five 
patients (83.3%) had a single hepatic lesion and the 
remaining 5 patients (16.7%) two hepatic lesions. Twenty 
patients (64.5%) had extrahepatic stable disease. The most 
frequent sites of primary tumor were colorectal (58%) and 
breast (20%). The majority of the lesions treated (75.6%) had 
a diameter of less than 3 cm. With a median follow-up of 21 
months (range 2.3-69.8 months) for all patients, “in field” 
local response rate was 90%. No patient developed a toxicity 
greater than grade 2 according to CTC scale v4.02 and no 
radio-induced liver disease (RILD) was recorded. One-year LC 
and two-year LC were 62% and 39% respectively. One-year 
and two-year PFS were 46% and 25% (median, 11 months). 
One-year, two-year and three-year OS were 89%, 69 and 42% 
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respectively, with a median survival time, calculated from 
the date of metastasis and last follow-up or death, of 29.8 
months. 
 
Conclusion: These data suggest that stereotactic ablative 
radiotherapy (SABR) is a safe, non-invasive and effective 
option in the treatment of liver metastases. 
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Purpose or Objective: The aim of this study was to 
investigate the outcome and prognostic factors for patients 
with locally advanced gastric cancer (LAGC) treated with 
adyuvant radiochemotherapy, according Macdonald scheme. 
 
Material and Methods: Between May 2004 and October 2014, 
a total of 106 patients, 70 men and 36 women, with locally 
advanced gastric cancer were treated in the University 
Hospital 12 de Octubre, Spain. The mean age was 57 years 
.The mean follow-up was 96.48 months. The most common 
tumor location was antrum (29.25%). The majority of tumors 
were T3 (52.83%) or T4 (22.64 %) and 86.79 % had nodal 
metastases, with an average of 8.24 nodes involved. 
Predominant histological subtype was diffuse (43.4%) and 
poorly differentiated (grade 3, 50%). Complete resection (R0) 
was achieved 84.91%, whereas microscopic residual disease 
(R1) was found in 13.21%. Survival was calculated by Kaplan-
Meier and method and differences were assessed by the Log-
rank test. Multivariate analysis was used Cox proportional 
hazards regression model. 
 
Results: A total of 50 (47.16 %) patients relapsed; 16 (15.09%) 
locoregional, 13 (12.26%) peritoneal, 18 (16.98%) distant 
metastases and 3 (2.83%) unknown. The overall survival (OS), 
disease-free survival ( DFS), locoregional failure-free survival 
(LFS) rates to three years were 48.75%, 46.27% and 76.72% 
and to five years were 32.11%, 38.78%, 69.67% respectively. 
In univariate analysis, T stage (T1-T2), N negative stage and 
R0 resection were associated with better survival (p<0.05) for 
OS and only N negative stage for DFS and LFS. In the 
multivariate analysis indentified only R0 resection as an 
independent predictor of better survival (p<0.05) for OS and 
DFS. 
 
Conclusion: In this study, the prognostic factors associated 
with better survival in patients with LAGC treated with 
adyuvant radiochemotherapy were: T stage (T1-T2), N 
negative stage and R0 resection ( p< 0.05). Complete R0 
resection also can be considered as independent prognostic 
factor of better survival (p<0.05) 
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Purpose or Objective: Activation of coagulation and 
fibrinolysis are found among gastric cancer patients. The 
ones with non-metastatic gastric cancer are at risk for 
thrombotic events due to the combined increase in fibrinogen 
plasma levels and thrombin formation. It could be associated 
with a higher risk of local invasion and might be important 
poor predictive and prognostic factor. In our study, we 
sought the associations between blood parameters and 
outcome 
 
Material and Methods: The study examined eighty-nine 
patients with biopsy-proven, operable gastric 
adenocarcinoma, with no evidence of distant metastases. 
Pre-operative fibrinogen, PT, APTT and INR levels were 
measured before surgery . Complete blood count were also 
collected before initiation of therapy . All patients 
underwent surgery as a primary treatment. The survival 
function was computed using Kaplan-Meier method. The 
overall survival (OS), Diseases- free survival (DFS), time to 
distant metastases (DM) and locoregional control (LRC) were 
calculated from the date of surgery. Multivariate analyses 
and characteristic (ROC) have been done. 
 
Results: In Multivariate Cox analysis higher level of WBC was 
associated with worse local control (p=0,0024), and shorter 
overall survival (p=0,0035). Shorter Prothrombin Time was 
correlated with better overall survival (p=0,0280). Higher 
Fibrinogen level has caused better local control (p=0,0280). 
No other correlation between DFS, LRC, DM and OS and other 
blood parameters were observed in multivariate analyses.  
 
Conclusion: The level of White Blood Cells, Fibrinogen and 
Prothrombin Time were found to be useful prognostic factor 
which influenced overall survival and local control. However, 
further prospective investigations are necessary to assess the 
predictive value of those factors. 
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Purpose or Objective: To evaluate the feasibility, efficacy 
and toxicity of robotic SBRT for the treatment of 
unresectable hepatic oligometastases. 
 
Material and Methods: Between 09/2010 and 01/2013, 15 
consecutive patients (12 female, 3 male, median age at 
treatment: 70.5, range: 57-85 years) with up to 3 
synchronous or metachronous hepatic oligometastases were 
referred for Cyberknife treatment (Accuray Incorporated, 
Sunnyvale, CA) at our center. In order to enable tumor 
tracking, gold fiducial markers were inserted around the 
lesion 2 weeks prior to each treatment. The treatment was 
delivered using the Synchrony Respiratory Tracking System to 
continuously track fiducial position and adjust for respiratory 
motion during treatment. Treatment planning was performed 
using the Multiplan TPS (v4.6, Accuray) with Raytracing 
algorithm, and was retrospectively recalculated using a 
Monte Carlo dose calculation algorithm (v5.1). The primary 
endpoint of this study was local control (LC), assessed with 
either contrast enhanced spiral CT or MRI. Secondary 
endpoints were liver and distant progression free-survival 
(liverPFS and DFS), overall survival (OS) and treatment 
toxicity, evaluated using the Common Terminology Criteria 
for Adverse Events v4.0. (Institute NC, NIH publication 2009). 
Statistical analysis was performed using R software (3.1.1, R 
Development Core Team 2010). 
 
Results: A total of 20 metastatic lesions were treated from 
primary colorectal (7), breast (7), unknown primary (3), 
melanoma (2) and stomach (1) cancer. The mean GTV and 
PTV volumes were 23.8cc (Standard deviation (SD):23) and 
74.5cc (SD:45.3) respectively. All treatments were delivered 
3x/week in a median three fractions (range: 3-6) to a median 
dose of 45 Gy (range: 30-45), prescribed to the 80% isodose 
line. This corresponds to an equivalent 2-Gy dose of 93.75Gy, 
